25/05/2026 – Following release of 2025 results and securing of clinical trial insurance policy, Maxim Group reiterates its buy recommendation on AB Science’s stock with a target price of EUR 4.0 per share Download PDF Post navigationPreviousPrevious post:Annual financial results as of 31 December, 2025NextNext post:Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per shareRelated PostsAB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026Annual financial results as of 31 December, 202513 May 2026AB Science announces the successful completion of a EUR 3.2 million private placement29 April 2026AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026
Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
